152PDDouble-blind, randomized phase III study to compare the efficacy and safety of trastuzumab and its biosimilar candidate CT-P6 in HER2 positive early breast cancer (EBC)
Esteva, F.J., Baranau, Y., Baryash, V., Manikhas, A., Moiseyenko, V., Dzagnidze, G., Zhavrid, E., Boliukh, D., Stroyakovskiy, D., Pikiel, J., Eniu, A., Komov, D., Zautashvili, Z., Morar-Bolba, G., Li,Volume:
28
Language:
english
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdx362.003
Date:
September, 2017
File:
PDF, 65 KB
english, 2017